Product Specifications: Lyophilized Powder (>99% purity) in 3ml vial. *Requires Reconstitution ** Available for bulk custom order with 57 Cap/Crimp colors to choose from.
Application: Research peptide evaluated in obesity and weight loss studies
Chemical Formula: C187H291N45O59
CAS Number: 910463-68-2
Molecular Weight: ~4113.6 g/mol
Concentration: ≥99%
Semaglutide, functioning as a glucagon-like peptide-1 (GLP-1) receptor agonist, is tested for weight loss as it mimics the naturally occurring hormone GLP-1 and primarily stimulates insulin secretion in the human pancreas.
Clinical Benefits
1. Metabolic Health Benefits
- Improved glycemic control
- Enhanced insulin sensitivity
- Better lipid profiles
2. Weight Management Benefits
- Substantial weight reduction (up to 15.3% over 68 weeks)
- Sustained long-term weight loss maintenance
3. Cardiovascular Protection
- Reduced MACE risk
- Improved cardiovascular outcomes across diverse patient populations
- Reduction in cardiovascular risk factors
4. Additional Clinical Benefits
- Liver health and fibrosis improvement
- Enhanced kidney function
- Potential sleep apnea management benefits
Primary Research Applications
1. Type 2 Diabetes Treatment
Research demonstrates significant metabolic benefits including:
- Substantial improvements in glycemic control through multiple Phase 2 and 3 trials
- Combined benefits of weight reduction and enhanced insulin sensitivity
- Ongoing investigation of long-term metabolic outcomes
2. Obesity Management
Studies show remarkable promise with:
- Unprecedented weight loss of up to 15.3% over 68 weeks (STEP-1 trial)
- Superior efficacy compared to other treatments, including liraglutide
- High completion rates (81%) in 52-week trials demonstrating strong tolerability
- Long-term efficacy studies extending to three years (pending ECO 2025 results)
3. Cardiovascular and Heart Failure Management
Significant cardiovascular benefits include:
- 26% reduction in risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease
- Improved cardiovascular outcomes in type 2 diabetes patients
- Potential cardiovascular risk reduction in obesity patients
4. Metabolic Associated Steatohepatitis (MASH/NASH)
Emerging research demonstrates:
- Superior efficacy compared to placebo for MASH resolution
- Over 50% of patients showing improved fibrosis at 52 weeks
- Potential for reducing hepatic inflammation and reversing fibrosis
Future Research Directions
Current research expansion focuses on:
- Extended long-term safety and efficacy profiles beyond three years
- Optimization of patient selection and treatment strategies
- Comparative effectiveness studies versus existing treatments
- Investigation of novel therapeutic applications in related metabolic conditions
References:
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024). Anti-inflammatory effect of semaglutide: Updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1379189
Kyrillos, J. V., Skolnik, N. S., Mukhopadhyay, B., & Pennings, N. (2022). Integrating semaglutide into obesity management - A primary care perspective. Postgraduate Medicine, 134(sup1), 37-49. https://doi.org/10.1080/00325481.2022.2149964
Disclaimer: This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes. Researchers should handle all peptides with care and adhere to strict safety guidelines during experiments. Only qualified professionals with appropriate expertise should manage and handle this product. The distributor, manufacturer, and seller of this product are not responsible for misuse or any resulting consequences. By accessing this product, you consent to comply with these terms and conditions.
